CN100554257C - 1-(4-苄基-哌嗪-1-基)-3-苯基-丙烯酮衍生物 - Google Patents

1-(4-苄基-哌嗪-1-基)-3-苯基-丙烯酮衍生物 Download PDF

Info

Publication number
CN100554257C
CN100554257C CNB2003801020110A CN200380102011A CN100554257C CN 100554257 C CN100554257 C CN 100554257C CN B2003801020110 A CNB2003801020110 A CN B2003801020110A CN 200380102011 A CN200380102011 A CN 200380102011A CN 100554257 C CN100554257 C CN 100554257C
Authority
CN
China
Prior art keywords
chloro
phenyl
methyl
benzyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801020110A
Other languages
English (en)
Chinese (zh)
Other versions
CN1708489A (zh
Inventor
B·博尔巴克
J·埃德
R·亨格
L·雷韦斯茨
A·施拉普巴赫
R·韦尔克利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1708489A publication Critical patent/CN1708489A/zh
Application granted granted Critical
Publication of CN100554257C publication Critical patent/CN100554257C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB2003801020110A 2002-10-25 2003-10-24 1-(4-苄基-哌嗪-1-基)-3-苯基-丙烯酮衍生物 Expired - Fee Related CN100554257C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0224917.5 2002-10-25
GBGB0224917.5A GB0224917D0 (en) 2002-10-25 2002-10-25 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2009101474324A Division CN101570517A (zh) 2002-10-25 2003-10-24 1-(4-苄基-哌嗪-1-基)-3-苯基-丙烯酮衍生物

Publications (2)

Publication Number Publication Date
CN1708489A CN1708489A (zh) 2005-12-14
CN100554257C true CN100554257C (zh) 2009-10-28

Family

ID=9946616

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2003801020110A Expired - Fee Related CN100554257C (zh) 2002-10-25 2003-10-24 1-(4-苄基-哌嗪-1-基)-3-苯基-丙烯酮衍生物
CNA2009101474324A Pending CN101570517A (zh) 2002-10-25 2003-10-24 1-(4-苄基-哌嗪-1-基)-3-苯基-丙烯酮衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2009101474324A Pending CN101570517A (zh) 2002-10-25 2003-10-24 1-(4-苄基-哌嗪-1-基)-3-苯基-丙烯酮衍生物

Country Status (19)

Country Link
US (1) US7645760B2 (https=)
EP (1) EP1558594A2 (https=)
JP (1) JP2006505575A (https=)
KR (1) KR20050065620A (https=)
CN (2) CN100554257C (https=)
AR (1) AR043055A1 (https=)
AU (1) AU2003296559B2 (https=)
BR (1) BR0315662A (https=)
CA (1) CA2502633C (https=)
EC (1) ECSP055745A (https=)
GB (1) GB0224917D0 (https=)
MX (1) MXPA05004348A (https=)
NO (1) NO20052487L (https=)
PE (1) PE20040779A1 (https=)
PL (1) PL374893A1 (https=)
RU (1) RU2347782C2 (https=)
TW (1) TW200420545A (https=)
WO (1) WO2004037796A2 (https=)
ZA (1) ZA200502700B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
SE0400441D0 (sv) 2004-02-25 2004-02-25 Active Biotech Ab Novel Benzofurans and Indols
SE0400440D0 (sv) * 2004-02-25 2004-02-25 Active Biotech Ab Novel Cinnamic Amides
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
FR2902426B1 (fr) * 2006-06-19 2008-09-05 Pierre Fabre Medicament Sa Derives de cinnamoyl-piperazine
WO2008090357A2 (en) * 2007-01-24 2008-07-31 Palatin Technologies, Inc. N, n; -substituted piperazines binding to melanocortin receptor
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
HRP20141190T1 (hr) * 2010-01-29 2015-01-30 Otsuka Pharmaceutical Co., Ltd. Disupstituirani derivati piridina kao antikancerogena sredstva
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
ES2682217T3 (es) 2012-08-08 2018-09-19 Mitsubishi Tanabe Pharma Corporation Método para producir un compuesto de 1,4-benzoxazina
US9993497B2 (en) * 2012-12-30 2018-06-12 Hadasit Medical Research Services And Development Ltd. Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent
AP2016009020A0 (en) * 2013-07-18 2016-02-29 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
WO2015048570A2 (en) * 2013-09-26 2015-04-02 Sanford-Burnham Medical Research Institute Ebi2 modulators
WO2016116875A1 (en) * 2015-01-20 2016-07-28 Novartis Ag Pet imaging agents
EP4065112A4 (en) * 2019-11-22 2023-12-27 The Regents of the University of California Taspase1 inhibitors and uses thereof
US20230062100A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0209843A2 (en) * 1985-07-16 1987-01-28 Kanebo, Ltd. Benzylpiperazine compound, preparation thereof, pharmaceutical composition, and use
JP2000086603A (ja) * 1998-07-15 2000-03-28 Yoshitomi Pharmaceut Ind Ltd 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60139646A (ja) * 1983-12-27 1985-07-24 Otsuka Pharmaceut Factory Inc ナフタレン誘導体
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives
SE9201956D0 (sv) * 1992-06-25 1992-06-25 Kabi Pharmacia Ab Novel nicotinicacid esters
US5380726A (en) * 1993-01-15 1995-01-10 Ciba-Geigy Corporation Substituted dialkylthio ethers
FR2725445B1 (fr) * 1994-10-10 1996-10-31 Adir Nouveaux derives a structure 1-arylalkenyl 4-aryl alkyl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6110922A (en) * 1998-12-29 2000-08-29 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
OA12670A (en) * 2001-10-22 2006-06-20 Pfizer Prod Inc Piperazine derivatives with ccr1 receptor antagonist activity.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0209843A2 (en) * 1985-07-16 1987-01-28 Kanebo, Ltd. Benzylpiperazine compound, preparation thereof, pharmaceutical composition, and use
JP2000086603A (ja) * 1998-07-15 2000-03-28 Yoshitomi Pharmaceut Ind Ltd 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体

Also Published As

Publication number Publication date
ECSP055745A (es) 2005-07-06
WO2004037796A2 (en) 2004-05-06
US7645760B2 (en) 2010-01-12
NO20052487D0 (no) 2005-05-24
RU2347782C2 (ru) 2009-02-27
KR20050065620A (ko) 2005-06-29
RU2005115964A (ru) 2006-01-27
CA2502633C (en) 2011-02-01
CA2502633A1 (en) 2004-05-06
NO20052487L (no) 2005-05-24
WO2004037796A3 (en) 2004-06-17
AR043055A1 (es) 2005-07-13
BR0315662A (pt) 2005-08-30
TW200420545A (en) 2004-10-16
CN101570517A (zh) 2009-11-04
PE20040779A1 (es) 2004-12-21
EP1558594A2 (en) 2005-08-03
AU2003296559A1 (en) 2004-05-13
US20060173004A1 (en) 2006-08-03
MXPA05004348A (es) 2005-08-02
GB0224917D0 (en) 2002-12-04
CN1708489A (zh) 2005-12-14
JP2006505575A (ja) 2006-02-16
AU2003296559B2 (en) 2007-11-01
ZA200502700B (en) 2006-05-31
PL374893A1 (en) 2005-11-14

Similar Documents

Publication Publication Date Title
CN100554257C (zh) 1-(4-苄基-哌嗪-1-基)-3-苯基-丙烯酮衍生物
RU2104268C1 (ru) Индолиновые производные, способ их получения, промежуточные соединения, фармацевтическая композиция
US5338755A (en) N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
US20050261290A1 (en) Novel compounds of proline and morpholine derivatives
JP5208510B2 (ja) 呼吸器疾患の処置に有用なフェノキシ酢酸誘導体
WO2003000181A2 (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
AU2002310465A1 (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
JP2005503369A (ja) メラノコルチン受容体のモジュレーターとしての置換ピペラジン
EA014498B1 (ru) Производные бензамидов в качестве антагонистов брадикининовых рецепторов
CN101754957A (zh) 新的杂环基化合物和它们作为趋化因子拮抗剂的用途
EP0524146A1 (de) Aminosubstituierte Piperazinderivate
CN102177136A (zh) 吡咯烷n-苄基衍生物
CN101679241B (zh) 作为nk3拮抗剂的脯氨酰胺衍生物
US20060189628A1 (en) Compounds useful as chemokine receptor antagonists
KR20120070609A (ko) 케모카인 수용체의 조절제로서 다이아제팜 유도체
US7288538B2 (en) Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
JPH04230358A (ja) α−メルカプトアルキルアミンの新規なＮ−置換誘導体、それらの製造法及び中間体、それらの薬剤としての使用並びにそれらを含有する組成物
CN101448785B (zh) 二肽基肽酶iv抑制剂、它们的制备方法以及含有它们的药物组合物
JP4486823B2 (ja) ヒドロキサム酸誘導体
JPH02262557A (ja) 縮合ベンゼン誘導体、それを含有する医薬及び該化合物の製造中間体
KR20100020026A (ko) Ｎｋ3 수용체 길항제로서 프롤린아마이드-테트라졸 유도체
HK1083834A (en) 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
WO1996024583A1 (en) Novel benzamidine derivatives and medicinal composition thereof
ZA200403189B (en) 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives or salts thereof.
HK1213566B (zh) 四唑酮衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1083834

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1083834

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091028

Termination date: 20141024

EXPY Termination of patent right or utility model